Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.77
- Piotroski Score 8.00
- Grade Buy
- Symbol (BDX)
- Company Becton, Dickinson and Company
- Price $225.42
- Changes Percentage (1.36%)
- Change $3.03
- Day Low $221.03
- Day High $225.80
- Year High $249.89
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
- Last Earnings 11/07/2024
- Ex-Dividend for 5/16 Dividend 12/09/2024
- Dividend Payable 12/31/2024
- Today N/A
- Next Earnings (Estimated) 02/06/2025
- Fiscal Year End N/A
- Average Stock Price Target $280.00
- High Stock Price Target $312.00
- Low Stock Price Target $255.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $4.66
- Trailing P/E Ratio 51.64
- Forward P/E Ratio 51.64
- P/E Growth 51.64
- Net Income $1.73 B
Income Statement
Quarterly
Annual
Latest News of BDX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Abingdon Health Plc's (LON:ABDX) Path To Profitability
Abingdon Health Plc is a UK-based company specializing in diagnostic devices. Analysts predict the company will break even in 2025 and turn a profit in 2026, with an 89% growth rate. The company's low...
By Yahoo! Finance | 1 month ago -
With 78% ownership, insiders at GSH Corporation Limited (SGX:BDX) are pretty optimistic and have been buying recently
GSH Corporation Limited's shareholder groups include insiders with a 78% stake, showing potential upside. Recent insider share purchases hint at positive stock performance. Institutional investors are...
By Yahoo! Finance | 1 month ago -
BCAL Diagnostics Limited's (ASX:BDX) Profit Outlook
BCAL Diagnostics Limited is close to breaking even with analysts predicting a profit in 2026. The company is expected to grow at an average annual rate of 91%. With low debt and judicious capital mana...
By Yahoo! Finance | 2 months ago
